Pegvisomant

Source: Wikipedia, the free encyclopedia.

Pegvisomant
Clinical data
Trade namesSomavert
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC990H1532N262O300S7
Molar mass22129.10 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegvisomant, sold under the brand name Somavert, is a

under the skin.[5]

Medical uses

Pegvisomant is

indicated for the treatment of adults with acromegaly.[1][2]

Side effects

Side effects of pegvisomant include reactions at the injection site, swelling of the limbs, chest pain, hypoglycemia, nausea and hepatitis.[6]

Discovery

Pegvisomant was discovered at Ohio University in 1987 by Distinguished Professor

FDA in 2003 and marketed by Pfizer.[7]

Structure

Pegvisomant is a protein containing 191 amino acid residues to which several polyethylene glycol polymers have been covalently bound in order to slow clearance from the blood.[5] The protein is a modified version of human growth hormone designed to bind to and block the growth hormone receptor. It is manufactured using genetically modified E. coli bacteria.[5]

Mechanism of action

Pegvisomant blocks the action of growth hormone on the growth hormone receptor to reduce the production of IGF-1.[8][9] IGF-1 is responsible for most of the symptoms of acromegaly, and the normalization of its levels can control the symptoms.[10]

Long-term treatment studies with pegvisomant as a monotherapy have shown it to be safe,[4] and effective.[11]

Research

Some studies show the potential of using pegvisomant as an anti-tumor treatment for certain types of cancers.[12][13]

References

  1. ^ a b c "Somavert- pegvisomant kit". DailyMed. 18 November 2021. Retrieved 18 May 2022.
  2. ^ a b c "Somavert EPAR". European Medicines Agency. 17 September 2018. Retrieved 18 May 2022.
  3. S2CID 12121175
    .
  4. ^ .
  5. ^ a b c Scientific Discussion of Somavert (PDF) (Report). European Medicines Agency. 2004. Archived from the original (PDF) on 18 June 2018. Retrieved 17 February 2011.
  6. PMID 16728538
    .
  7. ^ "Ohio University, inventors to receive up to $52 million from drug license transactions". Ohio University. 15 February 2011. Archived from the original on 22 November 2016. Retrieved 21 November 2016.
  8. PMID 12670297
    .
  9. .
  10. ^ CEDAC Final REcommendation on Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.) (PDF) (Report). Canadian Agency for Drugs and Technologies in Health. 2 August 2006. Archived from the original (PDF) on 28 June 2021. Retrieved 22 December 2014.
  11. S2CID 19588354
    .
  12. .
  13. .

External links

  • "Pegvisomant". Drug Information Portal. U.S. National Library of Medicine.